ReviewProgress in neurobiology2017
Challenges in the development of therapeutics for narcolepsy.
Review in Progress in neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 56 citations in OpenAlex.
- Clinical pearls for the treatment of narcolepsy.The mental health clinician · 2025Article
- TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models.Scientific reports · 2024Article
- Translational approaches to influence sleep and arousal.Brain research bulletin · 2022Review
- Review
- Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future.Sleep · 2021Article
- Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.Psychopharmacology · 2021Article
- Compromised Dynamic Cerebral Autoregulation in Patients With Central Disorders of Hypersomnolence.Frontiers in neurology · 2021Article
- Article
- Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns.Nature and science of sleep · 2020Review
- Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
- Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1.Journal of sleep research · 2019Article
- Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.Sleep medicine reviews · 2019Review
- The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2018Review
- Deletion of Trace Amine-Associated Receptor 1 Attenuates Behavioral Responses to Caffeine.Frontiers in pharmacology · 2018Article
- Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics.Biological psychiatry · 2017Article
- Update on the treatment of narcolepsy: clinical efficacy of pitolisant.Nature and science of sleep · 2017Review
- Current and Future Treatment Options for Narcolepsy: A Review.Sleep science (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Narcolepsy is a neurological disorder that afflicts 1 in 2000 individuals and is characterized by excessive daytime sleepiness and cataplexy-a sudden loss of muscle tone triggered by positive emotions. Features of narcolepsy include dysregulation of arousal state boundaries as well as autonomic and metabolic disturbances. Disruption of neurotransmission through the hypocretin/orexin (Hcrt) system, usually by degeneration of the HCRT-producing neurons in the posterior hypothalamus, results in narcolepsy. The cause of Hcrt neurodegeneration is unknown but thought to be related to autoimmune processes. Current treatments for narcolepsy are symptomatic, including wake-promoting therapeutics that increase presynaptic dopamine release and anticataplectic agents that activate monoaminergic neurotransmission. Sodium oxybate is the only medication approved by the US Food and Drug Administration that alleviates both sleep/wake disturbances and cataplexy. Development of therapeutics for narcolepsy has been challenged by historical misunderstanding of the disease, its many disparate symptoms and, until recently, its unknown etiology. Animal models have been essential to elucidating the neuropathology underlying narcolepsy. These models have also aided understanding the neurobiology of the Hcrt system, mechanisms of cataplexy, and the pharmacology of narcolepsy medications. Transgenic rodent models will be critical in the development of novel therapeutics for the treatment of narcolepsy, particularly efforts directed to overcome challenges in the development of hypocretin replacement therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.